Articles

Diagnosis and treatment of peripheral T-cell lymphomas: Update recommendations of the Belgian Hematology Society (BHS)

BJH - volume 13, issue 2, march 2022

A. Wolfromm MD, S. Bailly MD, E. Van den Neste MD, PhD, M. André MD, PhD, K. Saevels MD, H. Antoine-Poirel MD, PhD, T. Tousseyn MD, PhD, V. Van Hende MD, S. Snauwaert MD, PhD, A. Janssens MD, PhD, C. Jacquy MD, PhD, C. Bonnet MD

SUMMARY

Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive diseases associated with poor outcomes. Recent progress in understanding of the biology and pathogenesis based on molecular profiling and next-generation sequencing has led to the introduction of new provisional entities in the World Health Organization (WHO) classification system of 2017 and to the emergence of new drugs.1 Previous Belgian guidelines were published in 2013.2 This review will discuss the diagnosis, work-up and treatment of PTCL including these advances as well as the limitation of the availability of drugs according to the Belgian reimbursement rules.

(BELG J HEMATOL 2022;13(2):65–80)

Read more

O.1 Real World Population-Based Exploration of the Pathology Subtyping and Treatment-Modalities of Diffuse Large B-Cell Lymphoma in Belgium in Relation to Survival

BJH - volume 11, issue Abstract Book BHS, february 2020

W. Daneels , M. Rosskamp , G. Macq , E.I. Saadoon , A. De Geyndt , F. Offner MD, PhD, H. Antoine-Poirel MD, PhD

Read more

Cytogenetic and molecular testing in lymphoma patients: Part 2

BJH - volume 9, issue 7, december 2018

H. Antoine-Poirel MD, PhD, P. Heimann MD, PhD

SUMMARY

It is now well demonstrated that cytogenetic and molecular testing are valuable tools for the diagnostic, prognostication and decision of treatment strategy in lymphoproliferative disorders. This study gives an overview of the genetic tests that represent current and future clinical assessment tools in the context of lymphoid malignancies. This review has been divided into two distinct but complementary parts. The already published part 1 addressed the genetic aspects of low grade B-cell lymphomas and very briefly described the different technical methods that can be used in routine practice for the clinical management of lymphoid malignancies. This second part covers aggressive B- and T/NK-cell lymphomas as well as Hodgkin lymphoma.

(BELG J HEMATOL 2018;9(7):266–78)

Read more

P.29 The multifaceted GATA2 gene in inherited myeloid malignancies: about a Belgian family

BJH - 2013, issue BHS Abstractbook, january 2013

H. Antoine-Poirel MD, PhD, M. Pasquet , C. Bellané-Chantelot , S. Tavitian , N. Prade , B. Beaupain , O. la Rochelle , A. Petit , P. Rohrlich , F. Ferrand , E. Van den Neste MD, PhD, H.L. Phuoc Nguyen , M. Vikkula , T. Lamy , M. Ouachée , V. Mansat-de Mas , J. Corre , C. Récher , G. Plat , F. Bachelerie , J. Donadieu , E. Delabesse

Read more